Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers
Journal of Gynecologic Oncology · 2024
DOI: 10.3802/jgo.2024.35.e103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Risako Ozawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Antibodies, Monoclonal, Humanized, Microsatellite Instability, DNA Methylation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center Research and Development.
Abstract (Originalsprache)
OBJECTIVE: The efficacy of pembrolizumab in patients with microsatellite instability (MSI)-high cancers has been reported; however, the differences in efficacy according to the subtypes of MSI-high endometrial cancers (ECs) remain unclear. MSI-high ECs are classified into at least 3 groups based on their molecular characteristics: MLH1 hypermethylated, Lynch-like syndrome (LLS)-associated, and Lynch syndrome (LS)-associated cancers. This study aimed to investigate whether the efficacy of pembrolizumab differs among these 3 groups, and if so, whether EPM2AIP1 immunohistochemistry (IHC), which correlates with MLH1 promoter methylation, can be used to rule out MLH1 methylation cases. METHODS: This study included 12 patients with MSI-high EC who received pembrolizumab treatment. Patients were categorized into 3 groups based on MLH1 methylation analysis and the Amsterdam Criteria: MLH1 hypermethylated (sporadic [SP]), LLS-associated, and LS-associated. Patients' medical records were retrospectively reviewed, and the efficacy of treatment was evaluated based on the response rate using the Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: The overall response rate was 75% (3/4) in the SP group, while it was 100% including one complete response patient in the LLS-associated and the LS-associated group, respectively. The sensitivity and positive predictive value of EPM2AIP1 IHC for MLH1 methylation were 100% and 66.7%, respectively. CONCLUSION: Pembrolizumab may be more effective in LLS and LS-associated groups. EPM2AIP1 IHC was less predictive than MLH1 methylation analysis; however, it may be useful for ruling out MLH1 methylation cases due to its high sensitivity. Further studies are needed to determine whether EPM2AIP1 IHC can predict pembrolizumab efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. tnishika@ncc.go.jp.
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Risako Ozawa, Tadaaki Nishikawa, Hiroshi Yoshida, Kouya Shiraishi, Tatsunori Shimoi, Tomoyasu Kato, Kan Yonemori
Förderung
- National Cancer Center Research and Development
Zitieren
APA
Ozawa, R., Nishikawa, T., Yoshida, H., Shiraishi, K., Shimoi, T., Kato, T., & Yonemori, K. (2024). Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e103
Vancouver
Ozawa R, Nishikawa T, Yoshida H, Shiraishi K, Shimoi T, Kato T, et al. Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e103
BibTeX
@article{Ozawa2024,
author = {Ozawa, Risako and Nishikawa, Tadaaki and Yoshida, Hiroshi and Shiraishi, Kouya and Shimoi, Tatsunori and Kato, Tomoyasu and Yonemori, Kan},
title = {Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers},
journal = {Journal of Gynecologic Oncology},
year = {2024},
doi = {10.3802/jgo.2024.35.e103}
}
EUVIMED